Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered NEV801 in Subjects With Advanced Malignancies

NCT02797795 is registered in ClinicalTrials.gov with Neovia Oncology Ltd. as lead sponsor.

NCT NCT02797795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02797795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered NEV801 in Subjects With Advanced Malignancies
Lead sponsor
Neovia Oncology Ltd.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2016
Completion date
December 31, 2023
Enrollment
78 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, solid tumors